The scientific impact of the Structural Genomics Consortium: a protein family and ligand-centered approach to medically-relevant human proteins
暂无分享,去创建一个
Brian D. Marsden | Wen Hwa Lee | Stefan Knapp | Udo C. T. Oppermann | Frank von Delft | Susanne Müller | Opher Gileadi | Kathryn L. Kavanagh | D. Doyle | S. Knapp | K. Kavanagh | S. Müller | F. von Delft | O. Gileadi | U. Oppermann | M. Sundström | F. Niesen | B. Marsden | Michael Sundström | W. H. Lee | Linda J. Ball | Declan A. Doyle | Frank H. Niesen | L. Ball
[1] M. Yaffe,et al. A Structural Basis for 14-3-3σ Functional Specificity*♦ , 2005, Journal of Biological Chemistry.
[2] Ruben Abagyan,et al. Disseminating structural genomics data to the public: from a data dump to an animated story. , 2006, Trends in biochemical sciences.
[3] J. Forman-Kay,et al. Solution structure of a Nedd4 WW domain–ENaC peptide complex , 2001, Nature Structural Biology.
[4] R. Liddington,et al. Crystal structure of a PDZ domain , 1996, Nature.
[5] J. Adamski,et al. Characterization of Human DHRS6, an Orphan Short Chain Dehydrogenase/Reductase Enzyme , 2006, Journal of Biological Chemistry.
[6] M. Yaffe,et al. The Structural Basis for 14-3-3:Phosphopeptide Binding Specificity , 1997, Cell.
[7] John Kuriyan,et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). , 2001, Cancer research.
[8] Michael B Yaffe,et al. How do 14‐3‐3 proteins work? – Gatekeeper phosphorylation and the molecular anvil hypothesis , 2002, FEBS letters.
[9] K. Kavanagh,et al. Structure of Human Phytanoyl-CoA 2-Hydroxylase Identifies Molecular Mechanisms of Refsum Disease* , 2005, Journal of Biological Chemistry.
[10] R. Thieringer,et al. Inhibition of 11β-HSD1 as a novel treatment for the metabolic syndrome: do glucocorticoids play a role? , 2005, Expert review of cardiovascular therapy.
[11] O. Fedoroff,et al. The Structure and Dynamics of Tandem WW Domains in a Negative Regulator of Notch Signaling, Suppressor of Deltex* , 2004, Journal of Biological Chemistry.
[12] Piero Rinaldo,et al. Fatty acid oxidation disorders. , 2002, Annual review of physiology.
[13] S. Knapp,et al. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[14] L. Johnson,et al. Protein Kinase Inhibitors: Insights into Drug Design from Structure , 2004, Science.
[15] M. Cooper,et al. The Role of 11 β-Hydroxysteroid Dehydrogenase in Central Obesity and Osteoporosis , 2000, Endocrine research.
[16] S. Knapp,et al. Crystal Structures of the p21-Activated Kinases PAK4, PAK5, and PAK6 Reveal Catalytic Domain Plasticity of Active Group II PAKs , 2007, Structure.
[17] Steven E Brenner,et al. The Impact of Structural Genomics: Expectations and Outcomes , 2005, Science.
[18] Stefan Knapp,et al. Structure and Regulation of the Human Nek2 Centrosomal Kinase* , 2007, Journal of Biological Chemistry.
[19] H. Hermeking,et al. 14-3-3 proteins in cell cycle regulation. , 2006, Seminars in cancer biology.
[20] J Günter Grossmann,et al. Structural basis for protein–protein interactions in the 14-3-3 protein family , 2006, Proceedings of the National Academy of Sciences.
[21] P. Cohen. Protein kinases — the major drug targets of the twenty-first century? , 2002, Nature reviews. Drug discovery.
[22] L. Cantley,et al. Recognition of Unique Carboxyl-Terminal Motifs by Distinct PDZ Domains , 1997, Science.
[23] Stefan Knapp,et al. Crystal structure of the SOCS2–elongin C–elongin B complex defines a prototypical SOCS box ubiquitin ligase , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[24] S. Smerdon,et al. Structure of a 14-3-3 protein and implications for coordination of multiple signalling pathways , 1995, Nature.
[25] F. Niesen,et al. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability , 2007, Nature Protocols.
[26] B. Walker,et al. 11β-Hydroxysteroid dehydrogenase Type 1 as a novel therapeutic target in metabolic and neurodegenerative disease , 2003, Expert opinion on therapeutic targets.
[27] S. Knapp,et al. Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM-1) kinase. , 2005, Journal of medicinal chemistry.
[28] F. Young. Biochemistry , 1955, The Indian Medical Gazette.
[29] H. Hermeking,et al. The crystal structure of the non-liganded 14-3-3σ protein: insights into determinants of isoform specific ligand binding and dimerization , 2005, Cell Research.
[30] Janet Newman,et al. Towards rationalization of crystallization screening for small- to medium-sized academic laboratories: the PACT/JCSG+ strategy. , 2005, Acta crystallographica. Section D, Biological crystallography.
[31] D. Campbell,et al. 14-3-3-affinity purification of over 200 human phosphoproteins reveals new links to regulation of cellular metabolism, proliferation and trafficking. , 2004, The Biochemical journal.
[32] G. Superti-Furga,et al. Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase , 2003, Cell.
[33] D. Bredt,et al. PDZ domain of neuronal nitric oxide synthase recognizes novel C-terminal peptide sequences , 1997, Nature Biotechnology.
[34] U. Oppermann. Type 1 11beta-hydroxysteroid dehydrogenase as universal drug target in metabolic diseases? , 2006, Endocrine, metabolic & immune disorders drug targets.
[35] R. Frank. Spot-synthesis: an easy technique for the positionally addressable, parallel chemical synthesis on a membrane support , 1992 .
[36] G J Kleywegt,et al. Validation of protein crystal structures. , 2000, Acta crystallographica. Section D, Biological crystallography.
[37] T. Pawson,et al. Proteomic, Functional, and Domain-Based Analysis of In Vivo 14-3-3 Binding Proteins Involved in Cytoskeletal Regulation and Cellular Organization , 2004, Current Biology.
[38] M. Bennett,et al. Inborn Errors of Mitochondrial Fatty Acid Oxidation , 2000, Critical reviews in clinical laboratory sciences.
[39] William Arbuthnot Sir Lane,et al. Comprehensive Proteomic Analysis of Interphase and Mitotic 14-3-3-binding Proteins* , 2004, Journal of Biological Chemistry.
[40] Y. Kato,et al. Regulation of drug transporters by PDZ adaptor proteins and nuclear receptors. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[41] Cheryl H Arrowsmith,et al. Solution NMR in structural genomics. , 2006, Current opinion in structural biology.
[42] John H. Lewis,et al. Crystal Structures of a Complexed and Peptide-Free Membrane Protein–Binding Domain: Molecular Basis of Peptide Recognition by PDZ , 1996, Cell.
[43] M. Vieth,et al. Kinomics-structural biology and chemogenomics of kinase inhibitors and targets. , 2004, Biochimica et biophysica acta.
[44] M. Vieth,et al. Kinomics: characterizing the therapeutically validated kinase space. , 2005, Drug discovery today.
[45] V. Hu. The Cell Cycle , 1994, GWUMC Department of Biochemistry Annual Spring Symposia.
[46] Victor S. Lobanov,et al. High-Density Miniaturized Thermal Shift Assays as a General Strategy for Drug Discovery , 2001 .
[47] K. Kavanagh,et al. Structural and biochemical characterization of human orphan DHRS10 reveals a novel cytosolic enzyme with steroid dehydrogenase activity. , 2007, The Biochemical journal.
[48] A. Wynshaw-Boris,et al. Role of 14-3-3 proteins in eukaryotic signaling and development. , 2005, Current topics in developmental biology.
[49] R. Liddington,et al. Crystal structure of the zeta isoform of the 14-3-3 protein , 1995, Nature.
[50] T. Hunter,et al. The Protein Kinase Complement of the Human Genome , 2002, Science.
[51] E. Raymond,et al. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. , 2006, Seminars in oncology.
[52] M. Sheng,et al. PDZ domain proteins of synapses , 2004, Nature Reviews Neuroscience.
[53] R. Frank. The SPOT-synthesis technique. Synthetic peptide arrays on membrane supports--principles and applications. , 2002, Journal of immunological methods.
[54] P. Nordlund,et al. Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination , 2006, Proceedings of the National Academy of Sciences.
[55] L. Guarente,et al. A Stress Response Pathway Involving Sirtuins, Forkhead and 14-3-3 Proteins , 2006, Cell cycle.
[56] R. Ghirlando,et al. Crystal Structure of the 14-3-3ζ:Serotonin N-Acetyltransferase Complex A Role for Scaffolding in Enzyme Regulation , 2001, Cell.
[57] D. Doyle,et al. Structure of PICK1 and other PDZ domains obtained with the help of self‐binding C‐terminal extensions , 2007, Protein science : a publication of the Protein Society.
[58] Kevin Cowtan,et al. research papers Acta Crystallographica Section D Biological , 2005 .
[59] Slawomir K. Grzechnik,et al. Shotgun crystallization strategy for structural genomics: an optimized two-tiered crystallization screen against the Thermotoga maritima proteome. , 2003, Acta crystallographica. Section D, Biological crystallography.
[60] P. Maček,et al. pH and temperature-induced molten globule-like denatured states of equinatoxin II: a study by UV-melting, DSC, far- and near-UV CD spectroscopy, and ANS fluorescence. , 1997, Biochemistry.
[61] R. Rosenfeld. Nature , 2009, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.
[62] J Pohl,et al. 14-3-3ζ Binds a Phosphorylated Raf Peptide and an Unphosphorylated Peptide via Its Conserved Amphipathic Groove* , 1998, The Journal of Biological Chemistry.
[63] A. McPherson,et al. Screening and optimization strategies for macromolecular crystal growth. , 1994, Acta crystallographica. Section D, Biological crystallography.